Bristol Myers Squibb's dasatinib (Sprycel) patent situation is complex, with multiple patents covering the drug and its uses. The year 2000 is not a primary date for dasatinib's core patents. Dasatinib was first patented by Bristol Myers Squibb in the mid-2000s, with key patents filed around 2005 and 2006, leading to its FDA approval in 2006 [1].
When does dasatinib patent exclusivity expire?
The original patents for dasatinib have largely expired or are nearing expiry. For example, U.S. Patent No. 7,576,110, which covers a crystalline form of dasatinib, was issued in 2009 and has an expiration date in 2027 [2]. Other patents related to methods of treatment and formulations also exist with varying expiry dates. DrugPatentWatch.com tracks these specific patent expirations, providing detailed timelines [1].
What are the key patents protecting dasatinib?
Key patents protecting dasatinib include those for its chemical composition, specific crystalline forms, methods of manufacturing, and methods of treating certain conditions like chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [2].
Are there any ongoing patent challenges for dasatinib?
Yes, dasatinib has faced patent challenges. Generic manufacturers have sought to invalidate certain patents or launch their versions of the drug, leading to litigation [3]. These challenges can impact the timeline for generic entry.
How does dasatinib compare to other CML treatments?
Dasatinib is a tyrosine kinase inhibitor (TKI) used to treat CML and Ph+ ALL. It is considered a second-generation TKI, offering an alternative to earlier drugs like imatinib (Gleevec) and a treatment option for patients who are resistant or intolerant to other TKIs [4].
What is the regulatory status of dasatinib generics?
As patents expire or are successfully challenged, regulatory bodies like the U.S. Food and Drug Administration (FDA) can approve generic versions of dasatinib. Several generic manufacturers have received approval for their dasatinib products [3].
What is the mechanism of action for dasatinib?
Dasatinib works by inhibiting multiple tyrosine kinases, including BCR-ABL and SRC family kinases. This inhibition blocks signaling pathways that promote the growth and survival of cancer cells in CML and Ph+ ALL [4].
What are the risks and side effects associated with dasatinib?
Common side effects of dasatinib include fluid retention, rash, diarrhea, and fatigue. More serious risks can involve cardiovascular issues, such as QTc prolongation, and pulmonary arterial hypertension [4].